Publications by authors named "Daniel J Freeman"

Claim this Profile
H
Head-mounted central venous access during optical recordings and manipulations of neural activity in mice.
Christine Liu, Daniel J Freeman, Stephan Lammel

Nat Protoc· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wild-Type Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.
Rafael G Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J Freeman

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 Activated T Cells.
Simon J Dovedi, Matthew J Elder, Chunning Yang, Suzanne I Sitnikova, Lorraine Irving, Daniel J Freeman

Cancer Discov· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing oncolytic virotherapy in cancer treatment.
Kevin Harrington, Daniel J Freeman, Beth Kelly, James Harper, Jean-Charles Soria

Nat Rev Drug Discov· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Jeanne Mendell, Daniel J Freeman, Wenqin Feng, Thore Hettmann, Matthias Schneider

EBioMedicine· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
Jeffrey Crawford, Paul Swanson, Paul Schwarzenberger, Alan Sandler, Diane Prager, Daniel J Freeman

J Thorac Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models.
Michael J Boedigheimer, Daniel J Freeman, Panteha Kiaei, Michael A Damore, Robert Radinsky

Neoplasia· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Ryan P Wurz, Longbin Liu, Kevin Yang, Nobuko Nishimura, Yunxin Bo, Daniel J Freeman

Bioorg Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
Mark H Norman, Kristin L Andrews, Yunxin Y Bo, Shon K Booker, Sean Caenepeel, Daniel J Freeman

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer.
Daniel J Freeman, Kevin McDorman, Selam Ogbagabriel, Carl Kozlosky, Bing-Bing Yang

Mol Cancer· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Adrian L Smith, Noel D D'Angelo, Yunxin Y Bo, Shon K Booker, Victor J Cee, Daniel J Freeman

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.
Markian M Stec, Kristin L Andrews, Shon K Booker, Sean Caenepeel, Daniel J Freeman

J Med Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparability study of 5 commercial KRAS tests.
Kelly Oliner, Todd Juan, Sid Suggs, Michael Wolf, Ildiko Sarosi, Daniel J Freeman

Diagn Pathol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azole-based inhibitors of AKT/PKB for the treatment of cancer.
Qingping Zeng, John G Allen, Matthew P Bourbeau, Xianghong Wang, Guomin Yao, Daniel J Freeman

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Daniel J Freeman, Tammy Bush, Selam Ogbagabriel, Brian Belmontes, Todd Juan

Mol Cancer Ther· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
Tim J Kruser, Eric A Armstrong, Amol J Ghia, Shyhmin Huang, Deric L Wheeler, Daniel J Freeman

Int J Radiat Oncol Biol Phys· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
Daniel J Freeman, Todd Juan, Maureen Reiner, J Randolph Hecht, Neal J Meropol

Clin Colorectal Cancer· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Rafael G Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J Freeman

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN regulates Mdm2 expression through the P1 promoter.
Chun-Ju Chang, Daniel J Freeman, Hong Wu

J Biol Chem· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.
Daniel J Freeman, Andrew G Li, Gang Wei, Heng-Hong Li, Nathalie Kertesz

Cancer Cell· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis